Diamond Hill Capital Management LLC Investment Advisor Purchases Shares of 57,247 Avanos Medical, Inc. $AVNS

Diamond Hill Capital Management LLC Investment Advisor acquired a new position in Avanos Medical, Inc. (NYSE:AVNS) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 57,247 shares of the company’s stock, valued at approximately $1,424,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Samson Rock Capital LLP bought a new stake in shares of Avanos Medical during the second quarter valued at approximately $14,928,000. Punch & Associates Investment Management Inc. lifted its holdings in shares of Avanos Medical by 61.9% in the first quarter. Punch & Associates Investment Management Inc. now owns 437,085 shares of the company’s stock worth $6,124,000 after buying an additional 167,085 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Avanos Medical during the second quarter worth $2,575,000. Thrivent Financial for Lutherans boosted its position in shares of Avanos Medical by 38.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 212,215 shares of the company’s stock worth $2,383,000 after acquiring an additional 58,451 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of Avanos Medical by 1,596,514.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock worth $167,287,000 after acquiring an additional 14,895,480 shares during the last quarter. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Stock Performance

Shares of Avanos Medical stock opened at $24.99 on Tuesday. The stock’s fifty day moving average is $24.96 and its two-hundred day moving average is $20.73. The company has a market capitalization of $1.17 billion, a PE ratio of -15.52 and a beta of 1.57. The company has a quick ratio of 1.40, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $25.49.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AVNS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, July 20th. Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Friday, June 5th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Avanos Medical currently has a consensus rating of “Reduce”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.